PortalPublikationenTumor-associated CD75s gangliosides and CD75s-bearing glycop...

Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin

Standard

Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. / Müthing, Johannes; Meisen, Iris; Kniep, Bernhard; Haier, Jörg; Senninger, Norbert; Neumann, Ulrich; Langer, Martin; Witthohn, Klaus; Milosević, Jadranka; Peter-Katalinić, Jasna.

in: FASEB J, Jahrgang 19, Nr. 1, 01.2005, S. 103-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Müthing, J, Meisen, I, Kniep, B, Haier, J, Senninger, N, Neumann, U, Langer, M, Witthohn, K, Milosević, J & Peter-Katalinić, J 2005, 'Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin', FASEB J, Jg. 19, Nr. 1, S. 103-5. https://doi.org/10.1096/fj.04-2494fje

APA

Müthing, J., Meisen, I., Kniep, B., Haier, J., Senninger, N., Neumann, U., Langer, M., Witthohn, K., Milosević, J., & Peter-Katalinić, J. (2005). Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J, 19(1), 103-5. https://doi.org/10.1096/fj.04-2494fje

Vancouver

Müthing J, Meisen I, Kniep B, Haier J, Senninger N, Neumann U et al. Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J. 2005 Jan;19(1):103-5. https://doi.org/10.1096/fj.04-2494fje

Bibtex

@article{8d827075187c4d25ba1f2a65b97acd14,
title = "Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin",
abstract = "The anticancer drug rViscumin, currently under clinical development, has been shown in previous studies to be a sialic acid specific ribosome inactivating protein (RIP). Comparative binding assays with the CD75s-specific monoclonal antibodies HB6 and J3-89 revealed rViscumin to be a CD75s-specific RIP due to identical binding characteristics toward CD75s gangliosides. The receptor gangliosides are IV6nLc4Cer, VI6nLc6Cer, and the newly characterized ganglioside VIII6nLc8Cer, all three carrying the Neu5Acalpha2-6Galbeta1-4GlcNAc motif. To elucidate the clinical potential of the rViscumin targets, CD75s gangliosides were determined in several randomly collected gastrointestinal tumors. The majority of the tumors showed an enhanced expression of CD75s gangliosides compared with the unaffected tissues. The rViscumin binding specificity was further investigated with reference glycoproteins carrying sialylated and desialylated type II N-glycans. Comparative Western blots of rViscumin and ricin, an rViscumin homologous but galactoside-specific RIP, revealed specific recognition of type II N-glycans with CD75s determinants by rViscumin, whereas ricin failed to react with terminally sialylated oligosaccharides such as CD75s motifs and others. This strict binding specificity of rViscumin and the increased expression of CD75s gangliosides in various tumors suggest this anticancer drug as a promising candidate for an individualised adjuvant therapy of human tumors.",
keywords = "Antibodies, Monoclonal, Antigens, CD, Antigens, Tumor-Associated, Carbohydrate, Antineoplastic Agents, Blotting, Western, Brain, Chromatography, Thin Layer, Electrophoresis, Polyacrylamide Gel, G(M1) Ganglioside, Gangliosides, Gastrointestinal Neoplasms, Glycoproteins, Granulocytes, Humans, Models, Statistical, Plant Preparations, Plant Proteins, Receptors, Drug, Ribosome Inactivating Proteins, Type 2, Ricin, Sialyltransferases, Spectrometry, Mass, Electrospray Ionization, Toxins, Biological",
author = "Johannes M{\"u}thing and Iris Meisen and Bernhard Kniep and J{\"o}rg Haier and Norbert Senninger and Ulrich Neumann and Martin Langer and Klaus Witthohn and Jadranka Milosevi{\'c} and Jasna Peter-Katalini{\'c}",
year = "2005",
month = jan,
doi = "10.1096/fj.04-2494fje",
language = "English",
volume = "19",
pages = "103--5",
journal = "FASEB J",
issn = "0892-6638",
publisher = "FASEB",
number = "1",

}

RIS

TY - JOUR

T1 - Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin

AU - Müthing, Johannes

AU - Meisen, Iris

AU - Kniep, Bernhard

AU - Haier, Jörg

AU - Senninger, Norbert

AU - Neumann, Ulrich

AU - Langer, Martin

AU - Witthohn, Klaus

AU - Milosević, Jadranka

AU - Peter-Katalinić, Jasna

PY - 2005/1

Y1 - 2005/1

N2 - The anticancer drug rViscumin, currently under clinical development, has been shown in previous studies to be a sialic acid specific ribosome inactivating protein (RIP). Comparative binding assays with the CD75s-specific monoclonal antibodies HB6 and J3-89 revealed rViscumin to be a CD75s-specific RIP due to identical binding characteristics toward CD75s gangliosides. The receptor gangliosides are IV6nLc4Cer, VI6nLc6Cer, and the newly characterized ganglioside VIII6nLc8Cer, all three carrying the Neu5Acalpha2-6Galbeta1-4GlcNAc motif. To elucidate the clinical potential of the rViscumin targets, CD75s gangliosides were determined in several randomly collected gastrointestinal tumors. The majority of the tumors showed an enhanced expression of CD75s gangliosides compared with the unaffected tissues. The rViscumin binding specificity was further investigated with reference glycoproteins carrying sialylated and desialylated type II N-glycans. Comparative Western blots of rViscumin and ricin, an rViscumin homologous but galactoside-specific RIP, revealed specific recognition of type II N-glycans with CD75s determinants by rViscumin, whereas ricin failed to react with terminally sialylated oligosaccharides such as CD75s motifs and others. This strict binding specificity of rViscumin and the increased expression of CD75s gangliosides in various tumors suggest this anticancer drug as a promising candidate for an individualised adjuvant therapy of human tumors.

AB - The anticancer drug rViscumin, currently under clinical development, has been shown in previous studies to be a sialic acid specific ribosome inactivating protein (RIP). Comparative binding assays with the CD75s-specific monoclonal antibodies HB6 and J3-89 revealed rViscumin to be a CD75s-specific RIP due to identical binding characteristics toward CD75s gangliosides. The receptor gangliosides are IV6nLc4Cer, VI6nLc6Cer, and the newly characterized ganglioside VIII6nLc8Cer, all three carrying the Neu5Acalpha2-6Galbeta1-4GlcNAc motif. To elucidate the clinical potential of the rViscumin targets, CD75s gangliosides were determined in several randomly collected gastrointestinal tumors. The majority of the tumors showed an enhanced expression of CD75s gangliosides compared with the unaffected tissues. The rViscumin binding specificity was further investigated with reference glycoproteins carrying sialylated and desialylated type II N-glycans. Comparative Western blots of rViscumin and ricin, an rViscumin homologous but galactoside-specific RIP, revealed specific recognition of type II N-glycans with CD75s determinants by rViscumin, whereas ricin failed to react with terminally sialylated oligosaccharides such as CD75s motifs and others. This strict binding specificity of rViscumin and the increased expression of CD75s gangliosides in various tumors suggest this anticancer drug as a promising candidate for an individualised adjuvant therapy of human tumors.

KW - Antibodies, Monoclonal

KW - Antigens, CD

KW - Antigens, Tumor-Associated, Carbohydrate

KW - Antineoplastic Agents

KW - Blotting, Western

KW - Brain

KW - Chromatography, Thin Layer

KW - Electrophoresis, Polyacrylamide Gel

KW - G(M1) Ganglioside

KW - Gangliosides

KW - Gastrointestinal Neoplasms

KW - Glycoproteins

KW - Granulocytes

KW - Humans

KW - Models, Statistical

KW - Plant Preparations

KW - Plant Proteins

KW - Receptors, Drug

KW - Ribosome Inactivating Proteins, Type 2

KW - Ricin

KW - Sialyltransferases

KW - Spectrometry, Mass, Electrospray Ionization

KW - Toxins, Biological

U2 - 10.1096/fj.04-2494fje

DO - 10.1096/fj.04-2494fje

M3 - SCORING: Journal article

C2 - 15520251

VL - 19

SP - 103

EP - 105

JO - FASEB J

JF - FASEB J

SN - 0892-6638

IS - 1

ER -